Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [18F]-florbetaben PET

NeuroImage

Volumn 84, Issue , 2014, Pages 843-853

  Brendel, Matthias ^a   Delker, Andreas ^a   Rötzer, Christina ^a   Böning, Guido ^a   Carlsen, Janette ^a   Cyran, Clemens ^a   Mille, Erik ^a   Gildehaus, Franz Josef ^a   Cumming, Paul ^b   Baumann, Karlheinz ^c   Steiner, Harald ^a   Haass, Christian ^a,d   Herms, Jochen ^a,d   Bartenstein, Peter ^a,d   Rominger, Axel ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d F Hoffmann La Roche ^*  (Germany)

Author keywords

Alzheimer's disease; Partial volume effect correction; Small animal PET; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; FLORBETABEN;

ALGORITHM; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN CORTEX; BRAIN LEVEL; BRAIN SIZE; CEREBELLUM; CONTROLLED STUDY; EXPERIMENTAL MOUSE; HISTOCHEMISTRY; ISOTOPE LABELING; LONGITUDINAL STUDY; MOUSE; NEUROIMAGING; NONHUMAN; OPTICAL RESOLUTION; PHANTOM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; VALIDATION STUDY;

ALZHEIMER'S DISEASE; APP-SWE; BACKGROUND SURROUND VOI; BAS; BASAL SURROUND VOI; BGR; CBL; CEREBELLUM; COMBINED BRAIN STRUCTURE VOI EXCEPT FRONTAL CORTICAL TARGET VOI AND CEREBELLUM; CORTEX; CTX; EFFECTS OF THERAPY; ET; FIELD OF VIEW; FOV; FRO; FRONTAL SURROUND VOI; FULL WIDTH AT HALF MAXIMUM; FWHM; GEOMETRIC TRANSFER MATRIX; GTM; HARDERIAN GLAND VOI; HGL; HIGH UPTAKE PART OF SUBDIVIDED MIX VOI; HIP; HIPPOCAMPUS; K670N; LOW UPTAKE PART OF SUBDIVIDED MIX VOI; M671L; MGM; MIX; MIX-HI; MIX-LO; MUTATION OF AMYLOID PRECURSOR PROTEIN; MÜLLER-GÄRTNER METHOD; PARTIAL VOLUME EFFECT CORRECTION; PARTIAL VOLUME EFFECTS; POINT SPREAD FUNCTION; PSF; PVE; PVEC; RMSE [%]; ROOT-MEAN-SQUARE-ERROR PERCENTAGE; SINGLE EXTRACEREBRAL SURROUND VOI; SMALL ANIMAL PET; SPI; SPINAL SURROUND VOI; SRR; SS-AMYLOID; SUP; SUPERIOR SURROUND VOI; TG; TRANSGENIC; WILD-TYPE; WT; [(18)F]-FLORBETABEN;

ALGORITHMS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANILINE COMPOUNDS; ANIMALS; AUTORADIOGRAPHY; BRAIN; DISEASE MODELS, ANIMAL; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHANTOMS, IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; STILBENES;

EID: 84885709706     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.09.017     Document Type: Article

References (33)

1. Cheng J.C., Shoghi K., Laforest R. Quantitative accuracy of MAP reconstruction for dynamic PET imaging in small animals. Med. Phys. 2012, 39:1029-1041.
2. Erlandsson K., Buvat I., Pretorius P.H., Thomas B.A., Hutton B.F. A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology. Phys. Med. Biol. 2012, 57:R119-R159.
3. Fukuyama H., Hayashi T., Katsumi Y., Tsukada H., Shibasaki H. Issues in measuring glucose metabolism of rat brain using PET: the effect of harderian glands on the frontal lobe. Neurosci. Lett. 1998, 255:99-102.
4. Klunk W.E., Bacskai B.J., Mathis C.A., Kajdasz S.T., McLellan M.E., Frosch M.P., Debnath M.L., Holt D.P., Wang Y., Hyman B.T. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol. 2002, 61:797-805.
5. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 2005, 25:10598-10606.
6. 18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol. Imaging Biol. 2009, 11:236-240.
7. Lehnert W., Gregoire M.C., Reilhac A., Meikle S.R. Characterisation of partial volume effect and region-based correction in small animal positron emission tomography (PET) of the rat brain. NeuroImage 2012, 60:2144-2157.
8. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., Staufenbiel M., Iwata N., Ono M., Saido T.C., Suzuki K., Mori H., Higuchi M., Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007, 27:10957-10968.
9. Mannheim J.G., Judenhofer M.S., Schmid A., Tillmanns J., Stiller D., Sossi V., Pichler B.J. Quantification accuracy and partial volume effect in dependence of the attenuation correction of a state-of-the-art small animal PET scanner. Phys. Med. Biol. 2012, 57:3981-3993.
10. 11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One 2012, 7:e31310.
11. Mille E., Cumming P., Rominger A., La Fougere C., Tatsch K., Wangler B., Bartenstein P., Boning G. Compensation for cranial spill-in into the cerebellum improves quantitation of striatal dopamine D(2)/(3) receptors in rats with prolonged [(1)(8)F]-DMFP infusions. Synapse 2012, 66:705-713.
12. Muller-Gartner H.W., Links J.M., Prince J.L., Bryan R.N., McVeigh E., Leal J.P., Davatzikos C., Frost J.J. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J. Cereb. Blood Flow Metab. 1992, 12:571-583.
13. Nandoe Tewarie R.D., Yu J., Seidel J., Rahiem S.T., Hurtado A., Tsui B.M., Grotenhuis J.A., Pomper M.G., Oudega M. Positron emission tomography for serial imaging of the contused adult rat spinal cord. Mol. Imaging 2010, 9:108-116.
14. 18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol. Aging 2012, 33:2561-2571.
15. Qi J., Leahy R.M. Resolution and noise properties of MAP reconstruction for fully 3-D PET. IEEE Trans. Med. Imaging 2000, 19:493-506.
16. Richards J.G., Higgins G.A., Ouagazzal A.M., Ozmen L., Kew J.N., Bohrmann B., Malherbe P., Brockhaus M., Loetscher H., Czech C., Huber G., Bluethmann H., Jacobsen H., Kemp J.A. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J. Neurosci. 2003, 23:8989-9003.
17. Rojas S., Herance J.R., Gispert J.D., Abad S., Torrent E., Jimenez X., Pareto D., Perpina U., Sarroca S., Rodriguez E., Ortega-Aznar A., Sanfeliu C. In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. Neurobiol. Aging 2013, 34:1790-1798.
18. 18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse. Synapse 2010, 64:313-322.
19. 18F-florbetaben PET. J. Nucl. Med. 2013, 54:1127-1134.
20. Rousset O.G., Ma Y., Evans A.C. Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 1998, 39:904-911.
21. 18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects. Synapse 2000, 37:81-89.
22. Rousset O.G., Collins D.L., Rahmim A., Wong D.F. Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J. Nucl. Med. 2008, 49:1097-1106.
23. Singh S., Kushwah A.S., Singh R., Farswan M., Kaur R. Current therapeutic strategy in Alzheimer's disease. Eur. Rev. Med. Pharmacol. Sci. 2012, 16:1651-1664.
24. 18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2012, 39:1784-1795.
25. Teipel S.J., Buchert R., Thome J., Hampel H., Pahnke J. Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression. Prog. Neurobiol. 2011, 95:547-556.
26. Thomas B.A., Erlandsson K., Modat M., Thurfjell L., Vandenberghe R., Ourselin S., Hutton B.F. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:1104-1119.
27. 18F]FDG uptake in mouse brain and heart using small animal PET. Nucl. Med. Biol. 2004, 31:251-256.
28. 11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:593-600.
29. Videen T.O., Perlmutter J.S., Mintun M.A., Raichle M.E. Regional correction of positron emission tomography data for the effects of cerebral atrophy. J. Cereb. Blood Flow Metab. 1988, 8:662-670.
30. 18)F-florbetaben in Alzheimer disease and other dementias. J. Nucl. Med. 2011, 52:1210-1217.
31. Virdee K., Cumming P., Caprioli D., Jupp B., Rominger A., Aigbirhio F.I., Fryer T.D., Riss P.J., Dalley J.W. Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders. Neurosci. Biobehav. Rev. 2012, 36:1188-1216.
32. Visser E.P., Disselhorst J.A., Brom M., Laverman P., Gotthardt M., Oyen W.J., Boerman O.C. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J. Nucl. Med. 2009, 50:139-147.
33. Ziegler-Graham K., Brookmeyer R., Johnson E., Arrighi H.M. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement. 2008, 4:316-323.